@article{Hu2022, 
author = {Ruibin Hu and Tao Liao and Yan Ren and Wenming Liu and Rui Ma and Xinyuan Wang and Qihui Lin and Guoxin Wang and Yongye Liang},
title = {Sensitively detecting antigen of SARS-CoV-2 by NIR-II fluorescent nanoparticles},
year = {2022},
journal = {Nano Research},
volume = {15},
number = {8},
pages = {7313-7319},
keywords = {coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), antigen detection, the second near-infrared (NIR-II) fluorophores, lateral flow assay},
url = {https://www.sciopen.com/article/10.1007/s12274-022-4351-1},
doi = {10.1007/s12274-022-4351-1},
abstract = {Early detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is an efficient way to prevent the spread of coronavirus disease 2019 (COVID-19). Detecting SARS-CoV-2 antigen can be rapid and convenient, but it is still challenging to develop highly sensitive methods for effective diagnosis. Herein, a lateral flow assay (LFA) based on fluorescent nanoparticles emitting in the second near-infrared (NIR-II) window is developed for sensitive detection of SARS-CoV-2 antigen. Benefiting from the NIR-II fluorescence with high penetration and low autofluorescence, such NIR-II based LFA allows enhanced signal-to-background ratio, and the limit of detection is down to 0.01 ng·mL−1 of SARS-CoV-2 antigen. In the clinical swab sample tests, the NIR-II LFA outperforms the colloidal gold LFA with higher overall percent agreement with the polymerase chain reaction test. The clinical samples with low antigen concentrations (~ 0.015–~ 0.068 ng·mL−1) can be successfully detected by the NIR-II LFA, but fail for the colloidal gold LFA. The NIR-II LFA can provide a promising platform for highly sensitive, rapid, and cost-effective method for early diagnosis and mass screening of SARS-CoV-2 infection.}
}